@entity1311 plus @entity900 in @entity5 of unknown primary site ( XXXX ).

@entity1 @entity135 @entity1143 @entity137 @entity3478 @entity5 @entity75 @entity16 @entity900 @entity1311 @entity409 @entity787 @entity1398 @entity3799 @entity420 @entity298
UNASSIGNED: 2123 @entity5 ( @entity5 ) consists of a heterogeneous group of @entity5 that have acquired the capacity to metastasize before the development of a clinically evident @entity75 . They represent about 5-10% of all @entity5 . This study was designed to evaluate the efficacy and @entity137 of @entity1311 / @entity900 combination chemotherapy in @entity1 with @entity5 . The rationale for choosing this combination is based on available clinical data that @entity1311 and @entity900 have shown considerable clinical activity in various common @entity5 including lung, breast, stomach, esophagus, @entity135 . From January 2001 to September 2003, 37 @entity1 with @entity5 received 21-day cycles of @entity1311 175 mg/m(2) i.v. and @entity900 60 mg/m(2) i.v. on day 1. 31 @entity1 had @entity420 subtypes. The @entity1 received a total of 138 cycles of chemotherapy. The median number of cycles of chemotherapy per @entity1 was 4. The median age of the @entity1 was 53 (range, 21-71) years. The male to female ratio was 1:2.1. Initial presentations were @entity3799 , @entity298 , @entity409 , pelvic mass, metastatic @entity3478 and @entity1143 . Of these @entity1 , 36 @entity1 were evaluable for efficacy and @entity137 . Of the evaluable and measurable 26 @entity1 , complete response was in 1 @entity1 , and partial response was in 10 @entity1 . The overall response rate was 42% (95% C.I., 23-61%). Stable disease was seen in 6 @entity1 , progressive disease in 9 @entity1 . Median time to progression was 4 (95% C.I., 1.3-6.8) months. Median overall survival was 11 (95% C.I., 8.3-13.5) months. No prognostic factor was identified in univariate analysis. However, @entity1 with good performance status and @entity1 with normal @entity787 level showed marginal progression-free survival benefits (good PS vs poor PS; 5.2 vs 2.7 months, p=0.065) (normal @entity787 vs abnormal @entity787 ; 5.2 vs 1.9 months, p=0.066). The major @entity137 were @entity16 and @entity1398 . Grade 4 @entity1398 occurred in 10 cases, but febrile @entity1398 was seen in 4 cases. Our data suggests that this @entity1311 / @entity900 combination regimen is well tolerated with an encouraging level of activity for @entity1 with @entity5 . No significant financial relationships to disclose.
